Kardi AI, a medtech company based in the Czech Republic, has closed a €5.3 million Series A funding round spearheaded by Callisto Health, a German healthtech investor. The round represents the largest capital raise by a Czech medtech firm to date, according to the startup's own account.

The funding syndicate included Česká spořitelna and Slovenská sporiteľňa, which participated through their respective corporate venture arms operating under the Seed Starter brand. Returning investors BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels also contributed capital. Following the investment, Kardi AI carries a valuation of €23 million. The company intends to deploy the capital toward geographic expansion across European and Asian markets, alongside development of fresh algorithms designed to forecast cardiac arrhythmia risk.

We are gradually moving beyond detecting heart rhythm disorders towards technology capable of identifying an increased risk before arrhythmia manifests. Nearly two billion people live in the markets where we already operate or are preparing to launch,

Vlastimil Hrabal, co-founder and CEO of Kardi AI

Hardware, software and clinical workflow

The core offering from Kardi AI combines a wearable chest strap equipped with an embedded ECG sensor that pairs with a smartphone application. The app leverages artificial intelligence to interpret the electrical recordings captured by the device. Users wear the strap throughout their daily routines, review findings in real time, and can share data with healthcare providers as needed. Extended monitoring windows enable detection of sporadic arrhythmias that frequently escape notice during brief clinical examinations. The technology does not generate diagnoses itself; instead, Kardi AI positions it as an information resource to support physician decision-making regarding subsequent treatment pathways.

The startup was established in Olomouc during 2022 by cardiologist Prof. Tomáš Skála, entrepreneur Stephen Burke, technologist Pavel Digaňa and product designer David Skála. Vlastimil Hrabal subsequently joined the founding team in the chief executive role.

Within the Czech market, Kardi AI maintains partnerships with more than 70 hospitals alongside over 20 corporate and employee-benefit clients. The platform serves more than 6,000 active users. The company entered the Slovak market several months prior, establishing relationships with more than 20 physicians, predominantly cardiologists, at facilities including Bory Hospital and the Corfil cardiology clinic. Distribution channels encompass hospital and clinic partnerships, direct sales via the company's own e-shop, Alza, and the online pharmacy Moja Lekáreň.

In May 2026, Kardi AI earned recognition as Best HealthTech Startup at the Global Startup Awards world championship, marking the first Czech startup to achieve this distinction.

European foothold, then India, Middle East and Southeast Asia

Kardi AI currently maintains operations across Czechia, Slovakia, Poland, Romania and Bulgaria. Germany represents the company's primary European growth objective, where it has completed trial deployments and is preparing market entry.

During July 2026, Kardi AI obtained an MD-15 import licence from India's Central Drugs Standard Control Organisation (CDSCO), authorising both hardware and software distribution. The Indian expansion will commence in Hyderabad, where the company is negotiating with healthcare partners and establishing commercial and supply-chain infrastructure. Launch activities are scheduled for the final quarter of 2026.

The company holds a Medical Device Registration Certificate from the United Arab Emirates' Ministry of Health and Prevention (MOHAP) and showcased its technology during a Czech business delegation to Abu Dhabi and Dubai. Middle Eastern growth forms part of the company's broader regional strategy. Kardi AI is finalising medical device clearance in Singapore, which will serve as a gateway to Southeast Asian markets including the Philippines, Indonesia and Vietnam.

The new capital will allow us to validate this technology at global scale and across patient demographics and pursue our ambition to become a leading provider of long-term ECG monitoring in these markets,

Vlastimil Hrabal

Investor perspectives

Dr. Stefan Eckhardt, representing Callisto Health, highlighted the team's achievement in developing a certified medical product with strong usability characteristics, and noted its established deployment across Central and Eastern European healthcare settings.

Česká spořitelna has offered Kardi AI to its workforce as an employee benefit programme since 2024. According to Tomáš Milota, CEO of Seed Starter at Česká spořitelna, "We are investing in a solution we have already validated internally, at a time when the company has achieved MDR certification and is preparing for its next growth phase."

For Slovenská sporiteľňa's Seed Starter initiative, Kardi AI marks the first healthtech investment in the fund's portfolio.